Endo Pharmaceuticals greenshoe exercised in full, upping stock offer to 33.35 million shares

By Jennifer Chiou

New York, Oct. 12 - Endo Pharmaceuticals Holdings Inc. said its 4.35-million share greenshoe was exercised in full, raising its secondary stock offering to 33.35 million shares.

On Oct. 5, the company priced the upsized offering of 29 million shares at $26.04 apiece for gross proceeds of $755.16 million. The deal was increased from 26 million shares.

Bear, Stearns & Co. Inc. and Citigroup Corporate and Investment Banking led the underwriting syndicate. Morgan Stanley, SG Cowen & Co., UBS Investment Bank, C.E. Unterberg, Towbin, Jefferies & Co., Inc. and JPMorgan were co-managers.

Most shares were sold by the company's largest shareholder, Endo Pharma LLC, an affiliate of Kelso & Co. Some company executive stockholders and directors also sold shares.

The Chadds Ford, Pa., company markets generic and branded drugs, including pain medications, such as Percocet and Percodan. The company's stock closed up $0.20 at $26.00 on Wednesday.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.